Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flotetuzumab Interphase for MRD+ AML
NCT05063123Phase 2Withdrawn
- Sponsor
- HOVON
- Start
- Jan 2022
- Primary completion
- Aug 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of flotetuzumab in acute myeloid leukemia (AML), sponsored by HOVON. Primary endpoint: Rate of CR/CRi without MRD. Planned start Jan 2022; status: withdrawn.
02
Drugs
flotetuzumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05063123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063123.